15 patients achieved complete tumor remission; 43 of 102 saw tumor reduction or elimination in international trial of amivantamab. Drug works via three mechanisms: blocks EGFR protein, inhibits MET escape pathway, and activates immune system to attack tumors.
Infobae
· Jun 02, 2026
· health
· 4 min de lectura
High
Verificación: Verificado
Experimental drug amivantamab eliminates tumors in treatment-resistant head and neck cancer
Patients with advanced head and neck cancer who exhausted standard treatments gained extended survival (median 12.5 months) and improved quality of life, including restored speech and normal eating.
◉
Health & Medicine
2812 artículos relacionados
FDA approves Wegovy for heart disease prevention, expanding blockbuste…
infobae · 99% coincidencia
El ARN mensajero abre camino a vacunas contra 30 enfermedades infeccio…
infobae · 90% coincidencia
Weight-Loss Drugs Show Promise in Reducing Alcohol Cravings, But Clini…
infobae · 90% coincidencia
WHO endorses GLP-1 weight-loss drugs, issues first clinical guidance a…
El Tiempo · 90% coincidencia
Ozempic: Riesgos crecientes por uso estético sin supervisión médica
Medio digital El Zorro Nortino · 90% coincidencia
Cobertura Relacionada
El Mostrador · Aug 23
Guía de alimentos a limitar para proteger la salud cardiovascular
Expertos recomiendan limitar embutidos, bebidas azucaradas y ultraprocesados para reducir riesgos cardiovasculares. La a…
OkDiario · Aug 23 La boca seca no es una molestia menor: cuándo consultar al médicoLa xerostomía o boca seca es un problema infradiagnosticado que afecta a una de cada tres personas mayores de 60 años, f…
Segre.com · Aug 23 Programa pionero de ejercicio monitorizado mejora la salud cardiopulmonar en LleidaUn programa pionero en Lleida utiliza ejercicio físico monitorizado y análisis de 30 variables metabólicas para mejorar …
El País · Aug 23 No habrá una vacuna contra el cáncer, sino una distinta para cada paciente y tumorModerna y MSD avanzan hacia la aprobación de una vacuna de ARN mensajero personalizada contra el melanoma que reduce un …
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
Medical breakthrough in cancer treatment has no direct geopolitical implications; this is a pharmaceutical development story without international relations consequences.
Escalation Risk
low
Confidence
HIGH
Lente Económico
📈
Amivantamab experimental drug shows 15% complete tumor elimination in treatment-resistant head and neck cancer, potentially creating new market opportunities in oncology therapeutics.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Biotechnology
Healthcare/Oncology
Medical Devices & Diagnostics
Health Insurance
Patients with treatment-resistant head and neck cancer gain a new therapeutic option with potential for extended survival (12.5 months median). Increased healthcare costs for new drug treatment, but potential reduction in palliative care expenses. May improve quality of life for subset of patients with limited alternatives.
Likely accelerated regulatory approval pathways (breakthrough therapy designation). Potential for expanded clinical trials and market access discussions. Healthcare systems must evaluate pricing and reimbursement strategies. May influence oncology treatment guidelines and standard-of-care protocols. Possible patent and intellectual property considerations for developers.